Therefore, HMGA1 and MYH9 play essential roles in gliomas, which should be considered as tumoral enhancers with significant value as unfavorable progression indicators for patients with glioma, and may serve as feasible therapeutic targets in the future. This evidence concerns the gene MYH9 and central nervous system cancer.